Cholestasis alters brain lipid and bile acid composition and compromises motor function in neonatal piglets

Autor: Nicole Lind Henriksen, Svend Høime Hansen, Matthew Domenic Lycas, Xiaoyu Pan, Thomas Eriksen, Lars Søndergaard Johansen, Richard R. Sprenger, Christer Stenby Ejsing, Douglas G. Burrin, Kerstin Skovgaard, Vibeke Brix Christensen, Thomas Thymann, Stanislava Pankratova

Publikováno v: Physiological Reports, Vol 10, Iss 13, Pp n/a-n/a (2022)

Abstract Infants with neonatal cholestasis are prone to neurodevelopmental deficits, however, the underlying pathogenesis is unclear. Lipid malabsorption and accumulation of potentially neurotoxic molecules in the blood such as bile acids are importa

Externí odkaz: https://doaj.org/article/aab40f1f653541c48ef750a8f0a429a6

Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea:a double-blind, randomised, placebo-controlled, phase 4 clinical trial

Autor: Christian Borup, Lars Vinter-Jensen, Søren Peter German Jørgensen, Signe Wildt, Jesper Graff, Tine Gregersen, Anna Zaremba, Trine Borup Andersen, Camilla Nøjgaard, Hans Bording Timm, Dominique Rainteau, Svend Høime Hansen, Jüri Johannes Rumessen, Lars Kristian Munck

Publikováno v: Borup, C, Vinter-Jensen, L, Jørgensen, S P G, Wildt, S, Graff, J, Gregersen, T, Zaremba, A, Borup Andersen, T, Nøjgaard, C, Timm, H B, Rainteau, D, Hansen, S H, Rumessen, J J & Munck, L K 2023, ' Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea : a double-blind, randomised, placebo-controlled, phase 4 clinical trial ', The Lancet Gastroenterology & Hepatology, vol. 8, no. 4, pp. 321-331 . https://doi.org/10.1016/S2468-1253(22)00401-0
Borup, C, Vinter-Jensen, L, Jørgensen, S P G, Wildt, S, Graff, J, Gregersen, T, Zaremba, A, Borup Andersen, T, Nøjgaard, C, Timm, H B, Rainteau, D, Hansen, S H, Rumessen, J J & Munck, L K 2023, ' Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea : a double-blind, randomised, placebo-controlled, phase 4 clinical trial ', The Lancet Gastroenterology and Hepatology, vol. 8, no. 4, pp. 321-331 . https://doi.org/10.1016/S2468-1253(22)00401-0

BACKGROUND: Bile acid diarrhoea is a common but overlooked cause of chronic watery diarrhoea. Plasma 7α-hydroxy-4-cholesten-3-one (C4) is an alternative to the gold standard tauroselcholic [75Se] acid (SeHCAT) test. Low-certainty evidence supports s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbf41f7b32203fdb9313268e555c9edb
https://vbn.aau.dk/da/publications/c80274c8-3cd1-40e6-abf9-e3d045ae85b4

Bilio-enteric flow and plasma concentrations of bile acids after gastric bypass and sleeve gastrectomy

Autor: Rune E. Kuhre, Samuel A.J. Trammell, Sten Madsbad, Markus Lauge Eiken L. Eiken, Maria S. Svane, Aleksander Eiken, Nils B. Jørgensen, Carsten Dirksen, Kirstine N. Bojsen-Møller, Jens S. Svenningsen, Jens J. Holst, Svend Høime Hansen, Jan L. Madsen, Nicolai J. Wewer Albrechtsen, Jens F. Rehfeld, Stefan Fuglsang

Publikováno v: International Journal of Obesity. 44:1872-1883

Bile acids in plasma are elevated after bariatric surgery and may contribute to metabolic improvements, but underlying changes in bile flow are poorly understood. We assessed bilio-enteric flow of bile and plasma bile concentrations in individuals wi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eb3415ff385b736828bd1d4afd4f0d23
https://doi.org/10.1038/s41366-020-0578-7

Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial

Autor: Palle Jeppesen, Lars O. Dragsted, Jens F. Rehfeld, Mark Hvistendahl, Filip K. Knop, David P. Sonne, Hannelouise Kissow, Rahim M. Naimi, Jens Pedersen, Svend Høime Hansen

Publikováno v: Hvistendahl, M K, Naimi, R M, Hansen, S H, Rehfeld, J F, Kissow, H, Pedersen, J, Dragsted, L O, Sonne, D P, Knop, F K & Jeppesen, P B 2022, ' Bile acid-farnesoid X receptor-fibroblast growth factor 19 axis in patients with short bowel syndrome: The randomized, glepaglutide phase 2 trial ', Journal of Parenteral and Enteral Nutrition, vol. 46, no. 4, pp. 923-935 . https://doi.org/10.1002/jpen.2224

Background: The gut-liver axis and enterohepatic circulation have gained increasing attention lately. Patients with short bowel syndrome (SBS) are, in fact, human knock-out models that may assist in the understanding of bile acid synthesis and regula

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::582e8d37ea4bf89bff151071128c2732
https://pubmed.ncbi.nlm.nih.gov/34287979

Glepaglutide, a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial

Autor: Hannelouise Kissow, Nikolaj Nerup, Lars O. Dragsted, L. H. Enevoldsen, A Steensberg, Rahim M. Naimi, Jens Pedersen, Steen Seier Poulsen, Lars Bo Svendsen, Stefan Fuglsang, Palle Jeppesen, Bolette Hartmann, Michael Patrick Achiam, Jens J. Holst, Mark Hvistendahl, Mark Berner Hansen, Rikard Ambrus, Ulrik Mouritzen, Svend Høime Hansen, Jan L. Madsen

Publikováno v: The lancet. Gastroenterologyhepatology. 4(5)

Summary Background Patients with short bowel syndrome might have impaired postprandial endogenous glucagon-like peptide-2 (GLP-2) secretion, which is required for optimal intestinal adaptation. We aimed to assess the therapeutic potential of glepaglu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3925369e7e8148aadbc5f28dccb9f603
https://pubmed.ncbi.nlm.nih.gov/30880175